Next |
home / stock / adgi / adgi message board
Subject | By | Source | When |
---|---|---|---|
Lets gooooo$$$ | INFINITI | investorshub | 03/30/2022 3:34:33 PM |
Let her run geez | INFINITI | investorshub | 03/30/2022 3:06:31 PM |
Going to burst mark it $$$ | INFINITI | investorshub | 03/30/2022 2:52:43 PM |
On watch | Penny chatter | investorshub | 03/30/2022 2:50:23 PM |
Possible | Penny chatter | investorshub | 03/30/2022 2:49:59 PM |
Im in looks good lets gooo | INFINITI | investorshub | 03/30/2022 2:34:19 PM |
Short SQUEEZE and HALT on the menu today. | November61 | investorshub | 03/30/2022 1:00:02 PM |
Can it test previous price zones? | jchords | investorshub | 03/30/2022 12:42:35 PM |
https://finviz.com/quote.ashx?t=$ADGI | TheFinalCD | investorshub | 03/30/2022 11:49:44 AM |
Adagio Therapeutics Announces ADG20 (adintrevimab) is the First | Awl416 | investorshub | 03/30/2022 11:20:58 AM |
Is not a data read out coming this month? | Tim696969 | investorshub | 03/14/2022 3:49:21 PM |
Not really! Antibodies direction is a solution that | November61 | investorshub | 02/22/2022 2:56:34 PM |
Novavax announced approval in Canada just last week | double_m | investorshub | 02/22/2022 1:24:01 PM |
This stock is so freaking disappointing! A whole | double_m | investorshub | 02/11/2022 10:52:25 PM |
Looking nice here ;-) $ADGI $$$$ | Man6677 | investorshub | 02/08/2022 8:30:45 AM |
SQUEEZE and FILL the Gaps! | November61 | investorshub | 02/07/2022 5:15:11 PM |
Bought more at 5.80. Confident on that one. | November61 | investorshub | 01/21/2022 9:15:08 PM |
Very good ! Thanks . | Man6677 | investorshub | 01/20/2022 3:18:16 PM |
January 16th: Listed on NASDAQ.com as one of | Disquisition | investorshub | 01/17/2022 1:19:57 AM |
Very disappointing today after the news . | Man6677 | investorshub | 01/13/2022 5:56:24 PM |
News, Short Squeeze, Breakout and More Instantly...
Adagio Therapeutics Inc. Company Name:
ADGI Stock Symbol:
NASDAQ Market:
Received emergency use authorization for PEMGARDA™, a monoclonal antibody (mAb) authorized in the U.S. for pre-exposure prophylaxis (PrEP) of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise PEMGARDA product availability in the U.S. anticipated i...
Analysis of secondary endpoint of symptomatic COVID-19 events in CANOPY is unrelated to regulatory filing or review, but may be hypothesis generating for future Invivyd discovery and development work Today’s update on Day 67 and Day 90 event rates is the first of two planned publ...
PEMGARDA (pemivibart) is authorized in the U.S. for PrEP of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise Emergency use authorization based on positive immunobridging data and on safety data from the CANOPY clinical trial along with ongoing in vitro ...